Ozempic maker Novo Nordisk (NVO) announced mixed results today for a phase 2 trial of an experimental weight loss pill that ...
The U.S. Federal Trade Commission sued the country's three largest pharmacy benefit managers on Friday, accusing them of ...
Novo Nordisk stock tumbled Friday — pulling Corbus into a steep dive — after its new obesity drug caused neuropsychiatric side effects.